Ion channels expression and function are strongly modified in solid tumors and vascular malformations

Antonella Biasiotta†, Daniela D’Arcangelo†, Francesca Passarelli2, Ezio Maria Nicodemi2* and Antonio Facchiano2*

Abstract

Background: Several cellular functions relate to ion-channels activity. Physiologically relevant chains of events leading to angiogenesis, cell cycle and different forms of cell death, require transmembrane voltage control. We hypothesized that the unordered angiogenesis occurring in solid cancers and vascular malformations might associate, at least in part, to ion-transport alteration.

Methods: The expression level of several ion-channels was analyzed in human solid tumor biopsies. Expression of 90 genes coding for ion-channels related proteins was investigated within the Oncomine database, in 25 independent patients-datasets referring to five histologically-different solid tumors (namely, bladder cancer, glioblastoma, melanoma, breast invasive-ductal cancer, lung carcinoma), in a total of 3673 patients (674 control-samples and 2999 cancer-samples). Furthermore, the ion-channel activity was directly assessed by measuring in vivo the electrical sympathetic skin responses (SSR) on the skin of 14 patients affected by the flat port-wine stains vascular malformation, i.e., a non-tumor vascular malformation clinical model.

Results: Several ion-channels showed significantly increased expression in tumors (p < 0.0005); nine genes (namely, CACNA1D, FXYD3, FXYD5, HTR3A, KCNE3, KCNE4, KCNN4, CLIC1, TRPM3) showed such significant modification in at least half of datasets investigated for each cancer type. Moreover, in vivo analyses in flat port-wine stains patients showed a significantly reduced SSR in the affected skin as compared to the contralateral healthy skin (p < 0.05), in both latency and amplitude measurements.

Conclusions: All together these data identify ion-channel genes showing significantly modified expression in different tumors and cancer-vessels, and indicate a relevant electrophysiological alteration in human vascular malformations. Such data suggest a possible role and a potential diagnostic application of the ion–electron transport in vascular disorders underlying tumor neo-angiogenesis and vascular malformations.

Keywords: Cancer, Ion-channels, Autonomic nervous system, Sympathetic skin response, SSR, Flat port-wine stains

Background

Several key cellular functions are related to transmembrane potentials and lie under the control of ion channels, pumps and gap junction complexes. Controlling transmembrane voltage represents a fundamental process in many physiologically relevant steps, including cell cycle progression [1] and different forms of cell death [2, 3]. Over expression or increased activity of ion channels has been demonstrated as a response to mitogens exposure [4–6]. Several studies show a direct link between the transmembrane ion flow and carcinogenesis [7, 8]. However, as pointed out [9], the role membrane potential plays in the pathogenesis of several disorders, including cancer, is still not well understood. Plasma
membrane de-polarization has a pivotal role at different stages of cell cycle progression and in various cell types [9]. Namely, endothelial cells hyper-polarization has been shown to contribute to cell division arrest [10], and channels are known to control migratory cellular properties in wound healing [11]. Further, Ca\(^{2+}\), K\(^{+}\) and Cl\(^{-}\)channels are essential regulators of cell proliferation and cancer development [12–16]. As recently further demonstrated, several ion-channels are directly involved in controlling tumor—[17] as well as non-tumor angiogenesis [18]. Expression and activity of TRPV4 channel have been found suppressed in tumor endothelium [19], and its activation has been found to normalize tumor vessels [20]; inhibiting Cl\(^{-}\)channel activity has anti-angiogenesis and anti-glioma properties [21]; finally, human voltage-dependent K\(^{+}\) channel has been found associated with cancer aggressiveness and angiogenesis [22]. Therefore, ion-channels play a fundamental role in cancer progression as well as in angiogenesis.

Flat port-wine stains are non-tumor malformations of the skin capillaries [23]. Cutaneous capillary malformations are usually isolated finding. However, they may occasionally coexist with cerebral or ocular vascular malformations, constituting the rare sporadic neurocutaneous Sturge-Weber syndrome (SWS) affecting the cephalic microvasculature, or may represent signs of more aggressive vascular malformations or even vascular tumors. The sympathetic skin response (SSR) is an alteration in skin electrical potential evoked by strong stimuli; it consists of a multineuronal reflex activated by a variety of afferent inputs where the efferent branches involve sympathetic sudomotor fibers. The electrophysiological activity reflects sympathetic cholinergic sudomotor function which induces changes in skin resistance to electrical conduction. The response is mediated by ions flux via activation of receptor-coupled Ca\(^{2+}\), Cl\(^{-}\) and K\(^{+}\) channels [24]. Since SSR reflects peripheral C fibers activity, it is considered a reliable quantitative measure of sympathetic function and dysfunction as well as in polyneuropathies and dysautonomic disorders [25–27].

We have previously shown novel serum markers able to indicate cardiovascular diseases, [28, 29] as well as soluble factors able to affect angiogenesis [30] and to discriminate infantile hemangioma from more aggressive vascular malformations or tumors [31]. We also investigated novel molecular markers of melanoma set-up and progression [32].

In the present study, we further addressed the issue of altered angiogenesis in tumor and non-tumor conditions. The expression level of 90 ion-channel genes was investigated in five different solid tumors, having a different histological origin. The expression level of several ion-channels genes was found to be strongly modified; we thus hypothesized that ion-transport may represent a measurable sign of the altered underlying angiogenesis. We, therefore, measured in vivo the ion-channel function in a human vascular malformation model, namely flat port-wine stains, as a model to test electrical-stimuli transport in a human vascular disorder accepted by the Ethic Committee.

Methods

Ion-channel gene expression investigation

Gene expression levels were investigated by accessing human cancer datasets available at Oncomine (http://www.oncomine.org). The current Oncomine version contains several hundred different patients-datasets, referring to tumors biopsies obtained from almost any histological source; unfortunately vascular tumors (such as hemangioma, angiomas, hemangioendothelioma, angiosarcoma) are lacking from such database. In the current study 25, independent datasets from histologically different solid tumors were investigated, namely: bladder cancer, glioblastoma, melanoma, breast cancer, lung adenocarcinoma, as indicated in details in Table 1.

Table 2 reports the detailed list of the 90 ion-channels and ion-channel related genes investigated in the present study. Briefly, different members were selected from 21 channel families, namely: amiloride-sensitive cation channels, calcium Channels voltage-dependent, cation channels sperm associated, FXYD domain containing ion transport regulators, gamma-aminobutyric acid (GABA) receptors, glutamate receptors ionotropic, potassium channels voltage gated subfamily, chloride channels, cyclic nucleotide gated channels, glutamate Receptors, sodium leak channels, purinergic receptors P2X, sodium-hydrogen exchanger regulatory factor 4, regulatory solute carrier proteins, sodium channels, glucose activated Ion channels, two pore segment channels, transient receptor potential cation channels, zinc activated ion channels, aquaporins.

Expression of such 90 genes was evaluated in oncomine database by setting “cancer vs. normal analysis” and choosing as cancer type: “superficial bladder cancer” within the bladder cancer group, “glioblastoma” within the brain and CNS cancer group, “breast invasive ductal carcinoma” within the breast cancer group, “lung adenocarcinoma” within the lung cancer group, and “melanoma”.

Expression fold change (cancer vs. normal samples) and p values were reported for each analysis. Gene expression in tissue biopsies from 3673 patients was analyzed. Namely, 674 control-samples and 2999 cancer-samples were investigated.

Two additional datasets were identified and investigated within GEO database from NCBI (http://www.
ncbi.nlm.nih.gov/gds), namely GSE41614 and GSE44115. Such datasets specifically refer to the vessels component within cancer samples; they were analyzed by means of the GEO2R interface available at the http://www.ncbi.nlm.nih.gov/gds site.

**Patients recruitment**

Several reports indicate that direct electrical stimulation may affect cell proliferation and dissemination in oncological setups and may induce other physiological effects [33–39]. Thus a clinical-study involving any electrical stimulation in cancer patients would be not acceptable by the Ethic Committee, according to the articles n. 14 and n. 16 of the Helsinki declaration on biomedical studies involving human patients, and to the article n. 16 of the Oviedo Convention.

For such reasons we submitted to the Ethic Committee the request to authorize the in vivo investigation in non-tumor patients showing a pathological condition resembling, at least in part, the tumor neo-angiogenesis. Such request was authorized by the Ethic Committee and this explains way we investigated the SSR in angioma patients.

Fourteen patients (six males and eight females) affected by cutaneous flat port-wine stains were recruited at IDI-IRCCS, Rome. The study was approved by the institutional review board of IDI-IRCCS Hospital, Rome (IDI Ethic Committee 2011, n. 363). Patients with flat port-wine stains diagnosis (age 18–70 years) undergoing no
Table 2  Complete list of ion-channel genes and ion-channel related genes investigated

| Gene family | Gene name | Whole gene name |
|-------------|-----------|-----------------|
| **(A) Amiloride-sensitive cation channel** | | |
| 1 | ACCN1 | Amiloride-sensitive cation channel 1 |
| 2 | ACCN2 | Amiloride-sensitive cation channel 2 |
| 3 | ACCN3 | Amiloride-sensitive cation channel 3 |
| 4 | ACCN4 | Amiloride-sensitive cation channel 4 |
| **(B) Calcium channel, voltage-dependent** | | |
| 5 | CACNA1A | Calcium channel, voltage-dependent, P/Q type, alpha 1A Subunit |
| 6 | CACNA1B | Calcium channel, voltage-dependent, N type, alpha 1B Subunit |
| 7 | CACNA1C | Calcium channel, voltage-dependent, L type, alpha 1C Subunit |
| 8 | CACNA1D | Calcium channel, voltage-dependent, L type, alpha 1D Subunit |
| **(C) Cation channel, sperm associated** | | |
| 9 | CATSPER1 | Cation channel, sperm associated 1 |
| 10 | CATSPER2 | Cation channel, sperm associated 2 |
| 11 | CATSPER3 | Cation channel, sperm associated 3 |
| 12 | CATSPER4 | Cation channel, sperm associated 4 |
| **(D) FXYD domain containing ion transport regulator** | | |
| 13 | FXYD1 | FXYD domain containing ion transport regulator 1 |
| 14 | FXYD2 | FXYD domain containing ion transport regulator 2 |
| 15 | FXYD3 | FXYD domain containing ion transport regulator 3 |
| 16 | FXYD4 | FXYD domain containing ion transport regulator 4 |
| 17 | FXYD5 | FXYD domain containing ion transport regulator 5 |
| **(E) Gamma-aminobutyric acid (GABA) A receptor** | | |
| 18 | GABRA1 | Gamma-aminobutyric acid (GABA) A receptor, alpha 1 |
| 19 | GABRB3 | Gamma-aminobutyric acid (GABA) A receptor, beta 3 |
| 20 | GABRP | Gamma-aminobutyric acid (GABA) A receptor, Pi |
| **(F) Glutamate receptor, ionotropic** | | |
| 21 | GRIA1 | Glutamate receptor, ionotropic, AMPA 1 |
| 22 | GRIIN2A | Glutamate receptor, ionotropic, N-methyl-D-aspartate 2A |
| 23 | HTR3A | 5-Hydroxytryptamine (serotonin) receptor 3A, ionotropic |
| 24 | HTR3B | 5-Hydroxytryptamine (serotonin) receptor 3B, ionotropic |
| **(G) Potassium channel, voltage gated subfamily** | | |
| 25 | KCNE3 | Potassium channel, voltage gated subfam.E regulatory beta Sub. 3 |
| 26 | KCNE4 | Potassium channel, voltage gated subfam.E regulatory beta Sub. 4 |
| 27 | KCNH2 | Potassium channel, voltage gated Eag related subfamily H, member 2 |
| 28 | KCNH1 | Potassium channel, voltage gated Eag related subfamily H, Member 1 |
| 29 | KCNJ1 | Potassium channel, inwardly rectifying subfamily J, member 11 |
| 30 | KCNJ12 | Potassium channel, inwardly rectifying subfamily J, member 12 |
| 31 | KCNMA1 | Potassium channel, calcium activated large conductance subfam.M alpha, member 1 |
| 32 | KCNMB2 | Potassium channel subfamily M regulatory beta subunit 2 |
| 33 | KCNMB4 | Potassium channel subfamily M regulatory beta subunit 4 |
| 34 | KCNQ1 | Potassium channel, voltage gated KQT-Like Subfam. Q, Member 1 |
| 35 | KCNRG | Potassium channel regulator, protein CLLD4 |
| 36 | KCN1 | Potassium channel, voltage gated modifier subfamily V, Member 1 |
| 37 | KCNN1 | Potassium channel, calcium activated intermediate/small conductance subfamily N alpha, member 1 |
| 38 | KCNN2 | Potassium channel, calcium activated intermediate/small conductance subfamily N alpha, member 2 |
| 39 | KCNN3 | Potassium channel, calcium activated intermediate/small conductance subfamily N alpha, member 3 |
### Table 2 continued

| Gene family | Gene name | Whole gene name |
|-------------|-----------|-----------------|
| 40          | KCNN4     | Potassium channel, calcium activated intermediate/small conductance subfamily N alpha, member 4 |
| (H) Cholinergic receptor, nicotinic |           |                 |
| 41          | CHRNA1    | Cholinergic receptor, nicotinic, alpha 1 (muscle) |
| 42          | CHRNA2    | Cholinergic receptor, nicotinic, alpha 2 (neuronal) |
| 43          | CHRNA3    | Cholinergic receptor, nicotinic, alpha 3 (neuronal) |
| 44          | CHRNA5    | Cholinergic receptor, nicotinic, alpha 5 (neuronal) |
| (I) Chloride channel |       |                 |
| 45          | CFTR      | Cystic fibrosis transmembrane conductance regulator |
| 46          | BEST1     | Bestrophin 1    |
| 47          | CLCN1     | Chloride channel, skeletal muscle (CIC-1) |
| 48          | CLCN5     | Chloride channel, voltage-sensitive 5 (CIC-5) |
| 49          | CLIC1     | Chloride intracellular channel 1 |
| 50          | CLIC4     | Chloride intracellular channel 4 |
| (J) Cyclic nucleotide gated channel |       |                 |
| 51          | CNGB3     | Cyclic nucleotide gated channel beta 3 |
| (M) Glutamate receptor |       |                 |
| 52          | GRID1     | Glutamate receptor, ionotropic, delta 1 |
| 53          | GRID2     | Glutamate receptor, ionotropic, delta 2 |
| (N) Sodium leak channel |       |                 |
| 54          | NALCN     | Sodium leak channel, non selective |
| (O) Purinergic receptor P2X |       |                 |
| 55          | P2RX1     | Purinergic receptor P2X, ligand gated ion channel, 1 |
| 56          | P2RX2     | Purinergic receptor P2X, ligand gated ion channel, 2 |
| 57          | P2RX3     | Purinergic receptor P2X, ligand gated ion channel, 3 |
| 58          | P2RX4     | Purinergic receptor P2X, ligand gated ion channel, 4 |
| 59          | P2RX5     | Purinergic receptor P2X, ligand gated ion channel, 5 |
| 60          | P2RX6     | Purinergic receptor P2X, ligand gated ion channel, 6 |
| 61          | P2RX7     | Purinergic receptor P2X, ligand gated ion channel, 7 |
| (P) Sodium-hydrogen exchanger regulatory factor 4 |       |                 |
| 62          | PDZD3     | PDZ domain containing 3 |
| (Q) Regulatory solute carrier protein |       |                 |
| 63          | RSC1A1    | Regulatory solute carrier protein, family 1, member 1 |
| (R) Sodium channel |     |                 |
| 64          | SCN1A     | Sodium channel, voltage gated, type I alpha subunit |
| 65          | SCN2A     | Sodium channel, voltage gated, type II alpha subunit |
| 66          | SCN3A     | Sodium channel, voltage gated, type III alpha subunit |
| 67          | SCN4A     | Sodium channel, voltage gated, type IV alpha subunit |
| 68          | SCN5A     | Sodium channel, voltage gated, type V alpha subunit |
| 69          | SCN8A     | Sodium channel, voltage gated, type VIII alpha subunit |
| (S) Glucose activated ion channel |       |                 |
| 70          | SLC5A4    | Solute carrier family 5 (glucose activated ion channel) |
| (T) Two pore segment channel |       |                 |
| 71          | TPCN1     | Two pore segment channel 1 |
| 72          | TPCN2     | Two pore segment channel 2 |
| (W) Transient receptor potential cation channel |       |                 |
| 73          | TRPC1     | Transient receptor potential cation channel, subfamily C, member 1 |
| 74          | TRPC2     | Transient receptor potential cation channel, subfamily C, member 2 |
| 75          | TRPC3     | Transient receptor potential cation channel, subfamily C, member 3 |
| 76          | TRPC4     | Transient receptor potential cation channel, subfamily C, member 4 |
| 77          | TRPM1     | Transient receptor potential cation channel, subfamily M, member 1 |
treatment of any type were consecutively recruited. Patients did not show systemic or neurological disorders nor obvious psychological problems. Physical general and neurological examination were normal in all cases. The average lesion was about 25 cm × 10 cm, typically a portion of the limb. All patients signed an informed consent to participate in the study.

**Sympathetic skin responses SSR recording**

SSR study was carried out according to the technical standards of the International Federation of Clinical Neurophysiology [40]. During the test, subjects were kept relaxed with comfortable light and temperature (26–28 °C); the test was started after 5 min of previous adaptation. The apparatus used was an electromyography and evoked potential equipment (MedelecSynergy, Viasys Healthcare, Madison WI USA). Recording electrodes consisted of a pair of superficial electrodes: recording was carried out on the glabrous skin on the flat port-wine stain, and the reference was placed 2 cm away from the lesion. The ground electrode was proximal to the recording electrodes. Electrical stimulation was applied through superficial electrodes over the right median nerve. The stimulus was strong but tolerable (not noxious). The electrical stimulus was applied four times at irregular intervals of 30–60 s (stimulus duration: 0.1 ms; intensity: 80 mA) to avoid habituation, and SSR waves were obtained. SSR recordings were carried out in quadruplicates at the angiomas lesion sites and onto a contralateral healthy skin region in each patient.

The amplifier bandwidth was 0.1–100 Hz. Responses were recorded on the skin with an impedance <5 kΩ. The mean latency and peak-to-peak amplitude were calculated and used for the following analyses.

**Statistical analysis**

For gene expression data, the statistically significant threshold originally set at \( p = 0.05 \) was then corrected according to the Bonferroni correction for multiple comparisons, to take into account the multiple comparisons carried out. Therefore, the final corrected threshold was set at \( p < 0.0005 \) (value obtained from 0.05/90 comparisons, for each investigated dataset). The expression level of any given gene was considered to be significantly altered vs control when the significant \( p \) value was matched in at least half—or in at least 1—of the specific databases investigated for each tumor type. Namely, regarding the “at least half datasets” stringency level, the significant \( p \) value had to be matched in at least 2 datasets out of the 4 investigated for bladder cancer; in at least 2 datasets out of the 4 studied for glioblastoma; in at least 2 datasets out of the 4 examined for melanoma; in at least 3 datasets out of the 5 investigated for invasive ductal breast carcinoma; in at least 4 datasets out of the 8 investigated for lung adenocarcinoma.

SSR was recorded four consecutive times for each patient on the diseased skin and four consecutive times on the healthy contralateral skin. Mean ± SE was computed; mean latency and mean peak-to-peak amplitude recorded at the diseased-skin level were compared to measures obtained on the contralateral healthy control site. Paired t Student test was carried out, and statistical significance was set at \( p < 0.05 \). Normal distribution of SSR data was tested according to the D’Agostino-Pearson

### Table 2 continued

| Gene family | Gene name | Whole gene name |
|-------------|-----------|----------------|
| 77          | TRPM2     | Transient recep. potential cation channel, subfamily M, member 2 |
| 78          | TRPM3     | Transient recep. potential cation channel, subfamily M, member 3 |
| 79          | TRPM4     | Transient recep. potential cation channel, subfamily M, member 4 |
| 80          | TRPM7     | Transient recep. potential cation channel, subfamily M, member 7 |
| 81          | TRPV1     | Transient recep. potential cation channel, subfamily V, Member 1 |
| 82          | TRPV2     | Transient recep. potential cation channel, subfamily V, member 2 |
| 83          | TRPV3     | Transient recep. potential cation channel, subfamily V, member 3 |
| 84          | TRPV4     | Transient recep. potential cation channel, subfamily V, member 4 |
| 85          | ZACN      | Zinc activated ligand-gated ion channel |
| 86          | AQP1      | Aquaporin 1 |
| 87          | AQP2      | Aquaporin 2 |
| 88          | AQP3      | Aquaporin 3 |
| 89          | AQP4      | Aquaporin 4 |
| 90          | AQP5      | Aquaporin 5 |
test and carried out by the GraphPad software. Data with normal distribution were analyzed with the paired t test, while data with a not-normal distribution were analyzed with the non-parametric Wilcoxon match-paired signed ranked test.

Results

Expression level of ion-channels genes in tumors

The expression level of 90 ion-channels and ion-channels related genes (see Table 2 for the complete list) was analyzed in 3673 human biopsies of 5 histologically different solid tumors, namely: superficial bladder cancer, glioblastoma, melanoma, invasive ductal breast cancer, lung adenocarcinoma, as reported in Table 1 in more details.

Table 3 indicates the ion-channel families showing a significantly altered expression (p < 0.0005). For each cancer type, two columns are presented: the left-hand column (lighten) reports genes indicating a significantly modified expression in at least 1—or less than half-of the investigated datasets. The right-hand column of each tumor type (shadowed) reports in bold all genes showing a significantly modified expression in at least half of the examined datasets (see criteria detailed in "Methods" section). All genes matching the shadowed columns criteria were found overexpressed. More in detail:

- Within the calcium channel, voltage-dependent family, expression of CACNAD1 gene was found significantly modified in superficial bladder cancer datasets, namely in Dyrskjet dataset (p = 4 x 10^-6) and in Sanchez dataset (p = 5 x 10^-5), with an average 3.7-fold increase vs. ctrls;
- Within the FXYD domain containing ion transport regulator family, expression of FXYD3 gene was found significantly modified in bladder cancer (Dyrskjet dataset, p = 1 x 10^-6, Lee dataset, p = 3 x 10^-6 and Sanchez dataset, p = 6 x 10^-11) with an average 3.3-fold increase vs. ctrls. Furthermore, FXYD5 gene expression was found significantly modified in glioblastoma (in Lee dataset, p = 2 x 10^-5 and in Sun dataset, p = 1 x 10^-11) with an average 2.5-fold increase vs. ctrls;
- Within the glutamate receptor, ionotropic family, expression of HTR3A gene was found significantly modified in 5 lung carcinoma datasets, namely in Beer dataset (p = 3 x 10^-5), in Hou dataset (p = 7 x 10^-6), in Okayama dataset (p = 2 x 10^-13), in Selamat dataset (p = 1 x 10^-8), and in Landi dataset (p = 8 x 10^-6) with an average 5.08 fold increase vs ctrls;
- Within the potassium channel, voltage gated family, expression of three genes was found significantly modified in two cancer types. Namely, KCNE3 and KCNE4 genes are modified in glioblastoma datasets. KCNE3 shows an average 5.3-fold increase vs. ctrls (in Lee dataset, p = 3 x 10^-10 and in Sun dataset, 5 x 10^-8). KCNE4 shows an average 2.9-fold increase vs ctrls in Lee dataset (p = 1 x 10^-6) and in Sun dataset (p = 1 x 10^-13). KCNN4 was found altered in nearly all lung carcinoma datasets, namely in Bhattacharjee dataset (p = 1 x 10^-6), Stearman dataset (p = 3 x 10^-7), Hou dataset (p = 3 x 10^-9), Okayama dataset (p = 1 x 10^-8), Selamat dataset (p = 2 x 10^-14), Landi dataset (p = 2 x 10^-17) and in Sun dataset (p = 6 x 10^-8) with an average 3.6-fold increase vs ctrls;
- Within the chloride channel family, expression of CLIC1 gene was found significantly modified in bladder cancer (in Lee dataset, p = 8 x 10^-8 and Sanchez dataset, p = 3 x 10^-5) with an average 1.5-fold increase vs. ctrls. CLIC1 is also significantly modified in glioblastoma (in Bredel dataset, p = 3 x 10^-7 and Sun dataset, p = 2 x 10^-23) with an average 5.7-fold increase vs. ctrls;
- Within the transient receptor potential cation channel family, expression of TRPM3 gene is altered in glioblastoma, i.e., in the Lee dataset (p = 5 x 10^-9) and in the Sun dataset (p = 2 x 10^-5) with an average 2.3-fold increase vs. ctrls.

Within the shadowed columns, glioblastoma appears to have the highest number of modified ion-channel genes (namely: FXYD5, KCNE3, KCNE4, CLIC1, TRPM3).

Melanoma and breast cancer show no genes in the shadowed columns. However, within the lighten columns, breast invasive ductal cancer and melanoma show significantly modified ion-channel genes from 13 families and 6 families, respectively.

SSR recording in flat port-wine stains patients

The above reported analyses demonstrated that the expression level of several ion-channels is significantly altered in several human cancer biopsies. Such tumors are histological different. However, they all present an altered vascular tree, due to the tumor neo-angiogenesis. We hence hypothesized that vascular alterations observed in several different cancer types may harbor, at least to a certain extent, the observed ion-channels expression modifications. According to these findings, we hypothesized that measuring ion-channel transport may represent a non-invasive technique to investigate alterations in tumor- as well non-tumor altered angiogenesis. In vivo analysis of ion transport in a vascular malformation, the clinical model was carried out. In fact, measuring in vivo ion-transport in tumor patients was considered ethically not acceptable; we were then
forced to identify a non-tumor clinical condition showing clear vascular anomalies. The flat port-wine stains clinical model was approved by the Ethic Committee as a safe model to investigate Sympathetic Skin Responses and electrical signal transport, as the less invasive approach possible in the current study. SSR depends on Ca$^{2+}$, K$^+$, and Cl$^-$ channels found to be altered in Table 3.

Therefore, 14 patients with flat port-wine stains diagnosis were consecutively recruited, namely eight female (mean age 27 years) and six male (mean age 29.1 years). SSR recordings were carried out in quadruplicates at the angiomia lesion sites and onto a contralateral healthy skin region in each patient. Statistical analysis was performed with paired tests as reported in Methods.

### Table 3 Genes reported show a significantly altered expression in each cancer type

| Channel Family | Bladder cancer | Breast cancer | Glioblastoma | Lung carcinoma | Melanoma |
|----------------|----------------|---------------|--------------|----------------|----------|
|                | modified in at least 1 dataset | modified in at least half datasets | modified in at least 1 dataset | modified in at least half datasets | modified in at least 1 dataset | modified in at least half datasets |
| A              | ACCN1 ACCN3 | ACCN3 | | | | |
| B              | CACNAD1 CACNAD1 | CACNA1A CACNA1D | CACNA1A CACNA1B | | | |
| C              | CATSPER1 CATSPER2 | CATSPER1 CATSPER3 | CATSPER1 | | | |
| D              | FXYD5 FXYD3 | FXYD5 | FXYD5 | FXYD5 | | |
| E              | GABRB3 | GABRB3 | | | | |
| F              | GRIN2A HTR3A | HTR3A | HTR3A | GRIA1 GRIK1 | | |
| G              | KCNN1 KCNN4 | KCNE4 KCNE2 KCNH1 KCNH2 | KCNE3 KCNE4 KCMA1 KCNN1 KCNNQ1 KCNNR | KCNN4 KCNE4 KCNJ4 KCNNQ1 KCNN1 | KCNN13 KCNNQ1 KCNN2 |
| H              | CHRNA1 CHRNA2 CHRNA3 CHRNA5 | | CHRNA5 | | | |
| I              | CLICN5 CLIC1 | CLIC1 | CLIC1 | CLCN5 | CLCN1 | |
| L              | CNGB3 | CNGB3 | | | | |
| N              | NALCN | | | | | |
| O              | P2RX2 P2RX4 | P2RX4 | P2RX4 | P2RX4 P2RY13 | | |
| Q              | RSC1A1 | | | | | |
| R              | SCN1A SCN3A | SCN2A | SCN4A SCN8A | | | |
| T              | TPCN1 | TPCN1 | TPCN2 | | | |
| W              | TRPM2 TRPM4 TRPV4 | TRPM4 TRPV1 TRPV2 | TRPM3 TRPM3 | TRPC2 TRPM2 TRPV1 TRPV4 TRPV4 | TRPC4 TRPM1 |
| Z              | AQP3 | AQP2 AQP3 | AQP4 | AQP3 | | |

For each cancer type the lighten column reports ion-channels genes significantly modified in at least 1 dataset. The shadowed column reports ion-channels genes significantly modified in at least half of the investigated datasets. Channel family codes as in Table 2

Significance threshold: p < 0.0005 (see "Methods" section)
Figure 1 shows the mean latency and means amplitude measured at diseased and healthy sites, expressed in mV. A strong and significant reduction in both latency and peak-to-peak amplitude signals was observed in the diseased site as compared to the healthy site, in the whole patients population. When a gender-specific analysis was carried out, both latency and amplitude were strongly reduced in female patients, while latency was reduced in male, although in a not-significant manner.

Ion channel expression in normal vessels as compared to tumor derived vessels

Data reported in Table 3 and in Fig. 1 led us to hypothesize that ion channels genes may play a relevant role in cancers as well as in other pathological conditions of altered angiogenesis. To further support this hypothesis we investigated two human samples datasets available at GEO database. The first dataset (GSE41614) reports transcriptional profiling of tumor-associated blood vessels in human invasive bladder cancer samples. In such dataset the expression data were obtained on laser capture microdissected vessels isolated from normal bladder tissue or from tumor bladder tissues. Data from ten samples were analyzed, i.e., five normal samples vs five cancer samples.

The second dataset (GSE44115) reports gene expression data in OCT frozen human angiosarcoma compared to OCT frozen normal mesenchymal tissues. In this case 18 angiosarcoma samples were compared to four controls.

Discussion

It is widely known that nerves and vessels follow similar anatomical paths. Often nerves and vessels show an overlapping anatomy with overlapping branches and ramifications. Several molecular factors are reported to control their respective patterns and growth in a coordinated manner [41], including semaphorin, netrin and slit [42], all strongly regulated by Ca$^{2+}$, Na$^{+}$, and Cl$^{-}$ channels [43, 44]. Thus, an architectural or functional modification of the ones may affect the architecture or function of the others. We, therefore, argued that unordered angiogenesis occurring in tumors and vascular malformations may associate to a corresponding unordered nerve formation and therefore to a measurable alteration of the electric stimulus transport. We hypothesized that (i) ion channels (which are known to regulate nerve-
vessel-formation) may show altered expression in tumors and (ii) SSR recording in vascular malformations patients may unreveal a clinical non-invasive sign of the unordered vessels formation.

The expression level of members of several ion-channel families was found significantly modified in histologically different human cancer biopsies, according to the measures reported in Oncomine database, in an almost 4000 patients-vs-controls group. While several genes were found significantly modified (p < 0.0005) in at least one human dataset, we limit here the discussion to the genes reported in the shadowed columns of Table 3 selected according to highly stringent criteria, i.e. to the ion-channel genes found altered in at least half of the investigated databases of each tumor. We report in the current study that such genes show an increased expression in cancer vs. ctrls samples and have in most cases a definite role in vascular biology and/or cancer setup/progression or nervous system biology.

CACNA1D, a calcium related transporter gene, shows an average 3.75-fold increased expression in superficial bladder cancer datasets. No reports are present in

---

**Table 4  Ion channels genes most regulated in bladder cancer vessels vs control vessels**

| Rank position in the top 250 (by p value) | Gene identifier | Gene name                                      | Adjusted p value* | log2 fold change |
|-------------------------------------------|----------------|------------------------------------------------|-------------------|-----------------|
| 16th                                      | KCNC4          | Potassium voltage-gated channel subfamily C member 4 | 0.009             | +0.507          |
| 42th                                      | KCNG4          | Potassium voltage-gated channel modifier subfamily G member 4 | 0.01              | +0.415          |
| 75th                                      | VDAC3          | Voltage dependent anion channel 3              | 0.01              | -1.511          |
| 90th                                      | CRACR2B        | Calcium release activated channel regulator 2B | 0.01              | +0.472          |
| 115th                                     | KCNS2          | Potassium voltage-gated channel modifier subfamily S member 2 | 0.01              | +0.637          |
| 153th                                     | SEC23B         | Sec23 homolog B, coat complex II component (involved in vesicle trafficking) | 0.01              | -0.566          |
| 173th                                     | CBARP          | CACN Beta subunit associated regulatory protein | 0.01              | +0.627          |
| 218th                                     | P2RX5          | Purinergic receptor P2X 5 (ligand-gated ion channel) | 0.01              | +0.403          |
| 247th                                     | SCN2B          | Sodium voltage-gated channel beta subunit 2    | 0.02              | +0.487          |

* According to the Benjamini and Hochberg false discovery rate method

Data from Geo dataset GSE41614, available at [http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE41614](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE41614)

**Table 5  Ion channels genes most regulated in angiosarcoma vs controls**

| Rank position in the top 250 (by value) | Gene identifier | Gene name                                      | Adjusted p value* | log2 fold change |
|-----------------------------------------|----------------|------------------------------------------------|-------------------|-----------------|
| 3th                                     | KCNJ16         | Potassium voltage-gated channel subfamily J member 16 | 0.0000003         | +6.673          |
| 41th                                    | CLCNKA         | Chloride voltage-gated channel Ka              | 0.001             | +3.516          |
| 52th                                    | HCN2           | Hyperpolarization activated cyclic nucleotide gated potassium channel 2 | 0.001             | +2.099          |
| 53th                                    | KCNQ2          | Potassium voltage-gated channel subfamily Q member 2 | 0.001             | +1.276          |
| 61th                                    | FXYD4          | FXYD domain containing ion transport regulator 4 | 0.0009            | +6.247          |
| 75th                                    | CRACR2B        | Calcium release activated channel regulator 2B | 0.002             | +1.117          |
| 104th                                   | AQP10          | Aquaporin 10                                   | 0.004             | +2.096          |
| 125th                                   | KCNJ15         | Potassium voltage-gated channel subfamily J member 15 | 0.004             | +3.203          |
| 147th                                   | KCNK12         | Potassium two pore domain channel subfamily K member 12 | 0.004             | +2.008          |
| 153th                                   | FXYD2          | FXYD domain containing ion transport regulator 2 | 0.005             | +2.596          |
| 167th                                   | KCNJ1         | Potassium voltage-gated channel subfamily J member 1 | 0.01              | +3.369          |
| 250th                                   | AQP2           | Aquaporin 2                                    | 0.01              | +8.359          |

* According to the Benjamini and Hochberg false discovery rate method

Data from Geo dataset GSE44115, available at [http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE44115](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE44115)
literature referring CACNA1D direct link to bladder cancer. Nevertheless, some studies relate its expression- and methylation-level to prostate cancer [45, 46], indicating CACNA1D as a possible regulator of prostate cancer aggressiveness [47], or refer it to CNS disorders [48], diabetes [49] or calcium level within the vessels [50].

FXYD3 shows a 3.3 average fold increase expression in bladder cancer. It encodes a cell membrane protein regulating ion-pumps and ion-channels function and is known to have a role in tumor progression. Its activity is related to glucose and Cl− ions and has been indicated as a possible biomarker in bladder cancer [51, 52] as well as other cancers including breast [53], colorectal cancer [54], endometrial cancer [55] and intrahepatic cholangiocarcinoma [56].

FXYD5 is a transmembrane auxiliary subunit of the Na+-K+-ATPase; it shows a 2.5-fold increase in glioblastoma. No direct link with glioblastoma has been reported to date, however it has been found up-regulated in adamantinomatous craniopharyngiomas in children [57] and other members of the FXYD family are known to be associated with different cancer types such as urothelial carcinoma [58], esophageal squamous cell carcinoma [59] and cholangiocarcinoma [60]. FXYD channels are involved in the anti-oxidative stress in vascular smooth muscle, thus controlling the vascular tone [61] and blood pressure [62]. Most interestingly, expression of FXYD2 and FXYD4 genes is modified in angiosarcoma vs control human samples (Table 5).

The expression of serotonin receptor HTR3A was found increased by fivefold in lung carcinoma; no direct link has been reported between HTR3A and lung adenocarcinoma, yet; however, nucleotide polymorphisms of this gene have been related to opioid- or nausea/vomiting signaling pathways in cancer patients [63] and to bowel syndrome [64]. HTR3 is the only ligand-gated ion channel among the serotonin receptors, and it has been associated with neurological disorders such as depression [65] or schizophrenia [66]. Most interestingly about the current study, HTR3A acts as a ligand-gated ion channel neurotransmitter, and causes fast, depolarizing responses in neurons (http://www.genecards.org/cgi-bin/carddisp.pl?gene=HTR3A). It is up-regulated in rosacea, i.e., a chronic inflammatory skin disease often showing telangiectasias in the erythematotelangiectatic form (ETR) [67].

Within the potassium intermediate/small conductance calcium-activated channels, expression of 3 genes (namely KCNE3, KCNE4, KCN4) has been found altered in the current study, namely in glioblastoma and lung adenocarcinoma. While no direct evidence relate KCNE3 or KCNE4 to glioblastoma, KCNE4 is most abundantly expressed in brain [68]; it exerts functions such as controlling the neuronal firing rate, the synaptic transmission [69] and the T-lymphocytes maturation [70] and it is known to regulate K-channels in vascular smooth muscle [71] and more in general neuronal excitability. Furthermore, KCNN4 single-nucleotide polymorphisms have been related to myocardial infarction [72]. Most interestingly, KCNN4 has been linked to vascular cells proliferation [73]. Notably, expression of several potassium channels is modified in bladder cancer vessels vs controls (KCNC4, KCNG4, KCNS2, see Table 4) and in angiosarcoma vs controls (namely KCNJ16, KCNQ2, KCNJ15, KCNJ12, KCNJ1, see Table 5).

Within the Cl− intracellular channels, CLIC1 expression was found altered in bladder cancer and glioblastoma. CLIC1 has been previously found up-regulated in glioblastoma [74], it is involved in different tumors and acts as an oncogene in pancreatic cancer [75], and has been indicated as a possible cancer biomarker [76]. Interestingly, CLIC1 has recently shown a key role in angiogenesis control in combination with integrins [77, 78]. Interestingly, expression of one Cl− channel (namely CLCNKA) is strongly modified in angiosarcoma vs controls (see Table 5).

Within the transient receptor potential cation channels, TRPM3 gene expression was found increased in glioblastoma by 2.3-fold. Its expression has been previously found increased in glioblastoma [79] and is known to exhibit mechanosensitivity contributing to vascular and cardiac functions [80].

SSR is under the direct control of Ca2+, K−, Cl− ion channels and strictly depends on the sympathetic autonomous nerve function. In the current study, several ion channels related to the Ca2+, K+ and Cl− have relevant, and significantly increased expression in different human cancers and SSR was found strongly altered in human vascular malformations. SSR has been previously indicated as a possible useful diagnostic technique in CNS pathologies [81, 82], as well as fibromyalgia [83] and diabetes [84]. Further, autonomic nerve development and function has been recently shown to play a key role in prostate cancer progression [85]. Thus, given the known role of several ion channels in the tumor, nerve, and vascular biology, we hypothesize that the altered SSR observed in vascular skin malformations, and the observed altered ion-channel gene-expression in several tumors may represent phenomena related to the unordered nerve- and vessel formation, common to tumor-related and non-tumor-related vascular anomalies.

SSR recording gave more significant results in female while in male the trend was present but with no statistical significance. Such difference may be related to a different transport of electrical stimuli in the female skin, which appears evident at both healthy (white boxes in Fig. 1) and diseased sites (black boxes in Fig. 1), as
compared to male. A gender-related difference in the skin thickness may underlie, at least in part, such observation likely associated with the skin thickness and water retention induced by the menstrual phases and the hormonal status in females.

In conclusion, data reported in the current study allowed us to conclude that ion-channel expression and function may be strongly affected in pathological conditions where vessels’ (and nerves’) architecture is altered. SSR measurement may thus represent a non-invasive useful tool to investigate vascular skin alterations in both tumor and non-tumor conditions.

Conclusions
The present study reports for the first time a detailed analysis of the expression level of 90 ion-channel genes in 3673 biopsies form humans affected by solid tumors and from healthy controls. At least ten genes from different ion-channels families were found firmly and significantly up-regulated in histologically different tumors having in common the underlying unordered tumor neo-angiogenesis (Table 3). Moreover, expression of at least 20 ion channels has been found to be strongly modified in cancer associated vessels vs controls (Tables 4, 5). The sympathetic skin responses (SSR), an electrical feature closely related to the ion-channels activity, was then measured in vivo and was found strongly modified in the skin of patients affected by the flat port-wine stains vascular malformation. The present study indicates that modified expression and activity of ion channels is likely related to vascular alteration, in both tumor and non-tumor conditions, and suggests the non invasive technique SSR as a simple, useful tool to investigate skin vascular anomalies.

Authors’ contributions
AB, DD, EMN, AF: design of the study; data collection; data interpretation, writing. FP: data interpretation. All authors read and approved the final manuscript.

Author details
1 Department of Neurology and Psychiatry, Sapienza University, Rome, Italy.
2 Istituto Dermopatico dell’Immacolata, IDI-IRCCS, Fondazione Luigi Maria Monti, via Monti di Creta 104, 00167 Rome, Italy.

Competing interests
The authors declare that they have no competing interests.

Ethics approval and consent to participate
The study was approved by the institutional review board of IDI-IRCCS Hospital, Rome (IDI Ethic Committee 2011, n. 363). All patients signed an informed consent to participate in the study.

Funding
This study has been partially supported by Ministry of Health, Ric. Cor. 2013–2014, Line 3.4 to AF.

Received: 31 May 2016 Accepted: 21 September 2016 Published online: 04 October 2016

References
1. Blackiston DJ, McLaughlin KA, Levin M. Bioelectric controls of cell proliferation: ion channels, membrane voltage and the cell cycle. Cell Cycle. 2009;8:3527–36.
2. Kunzelmann K. Ion channels in regulated cell death. Cell Mol Life Sci. 2016;73(11–12):2387–403.
3. Alfarouk KO. Tumor metabolism, cancer cell transporters, and microenviron-mental resistance. J Enzyme Inhib Med Chem. 2016;31:859–66. doi:10.3109/14756366.2016.1140753.
4. Enomoto K, Cossu MF, Maeno T, Edwards C, Oka T. Involvement of the Ca2+-dependent K+ channel activity in the hyperpolarizing response induced by epidermal growth factor in mammary epithelial cells. FEBS Lett. 1986;203:181–4.
5. Campbell TM, Main MJ, Fitzgerald EM. Functional expression of the voltage-gated Na+ channel Nav1.7 is necessary for EGF-mediated invasion in human non-small cell lung cancer cells. J Cell Sci. 2013;126:4939–49.
6. Friede J, Fraser SP, Oskay-Ozcelik G, Hong Y, Ioana Bracu E, Sehoul J, Gabra H, Djungoz MB. Ovarian cancer: ion channel and aquaporin expression as novel targets of clinical potential. Eur J Cancer. 2013;49:2331–44.
7. Cone CD. Unified theory on the basic mechanism of normal mitotic control and oncogenesis. J Theor Biol. 1971;30:151–81.
8. Cone CD. Electroosmotic interactions accompanying mitosis initiation in sarcoma cells in vitro. Trans. N Y Acad Sci. 1969;31:404–27.
9. Bränström R, Chang Y-M, Kasparian N, Affleck P, Tibben A, Aspinwall LG, Azi ZE, Baron-Epel O, Battistuzzi L, Bruno W, Chan M, Cuellar F, et al. Melanoma risk factors, perceived threat and intentional tanning: an international online survey. Eur J Cancer Prev. 2010;19:216–26.
10. Wang E, Yin Y, Zhao M, Forrester JV, McCaig CD. Physiological electric fields control the G1/S phase cell-cycle checkpoint to inhibit endothelial cell proliferation. FASEB J. 2003;17:458–60.
11. Zhao M, Song B, Pu J, Wada T, Reid B, Tai G, Wang F, Guo A, Walczysko P, Gu Y, Sasaki T, Suzuki A, et al. Electrical signals control wound healing through phosphatidylinositol-3-0H kinase-gamma and PTEN. Nature. 2006;442:457–60.
12. Kunzelmann K. Ion channels and cancer. J Memb Biol. 2005;205:159–73.
13. Thongon N, Ketkeaw P, Nueckchob C. The roles of acid-sensing ion channel 1a and ovarian cancer G protein-coupled receptor 1 on passive Mg2+ transport across intestinal epithelium-like Caco-2 monolayers. J Physiol Sci. 2014;64:129–39.
14. Ko J-H, Ko EA, Gu W, Lim I, Bang H, Zhou T. Expression profiling of ion channel genes predicts clinical outcome in breast cancer. Mol Cancer. 2013;12:106.
15. Han X, Xi L, Wang H, Huang X, Ma X, Han Z, Wu P, Ma X, Lu Y, Wang G, Zhou J, Ma D. The potassium ion channel opener NS1619 inhibits prolif-eration and induces apoptosis in A2780 ovarian cancer cells. Biochem Biophys Res Commun. 2008;375:205–9.
16. D’Arcangelo D, Silletta MG, Di Francesco AL, Bonfitto N, Di Cerbo A, Falasca M, Corda D. Physiological concentrations of thryrotropin increase cytosolic calcium levels in primary cultures of human thyroid cells. J Clin Endocrinol Metab. 1995;80:1136–43.
17. Martial S. Involvement of ion channels and transporters in carcino-ma angiogenesis and metastasis. Am J Physiol Cell Physiol. 2016. doi:10.1152/ajpcell.00218.2015.
18. Shim JH, Lim JW, Kim BK, Park SJ, Kim SW, Choi TH. KCl mediates K(+) channel-activated mitogen-activated protein kinases signaling in wound healing. Arch Plast Surg. 2015;42:11–9.
19. Thoppill RJ, Cappelli HC, Adapala RK, Kanugula AK, Paruchuri S, Thodeti CK. TRPV4 channels regulate tumor angiogenesis via modulation of Rho/Rho kinase pathway. Oncotarget. 2016;7:25849–61.
20. Adapala RK, Thoppill RJ, Ghosh K, Cappelli HC, Dudley AC, Paruchuri S, Keshamouni V, Klagsbrun M, Meszaros JG, Chilian WM, Inger DE, Thodeti CK. Activation of mechanosensitive ion channel TRPV4 normalizes tumor vasculature and improves cancer therapy. Oncogene. 2016;35:314–22.
21. Xu T, Fan Z, Li W, Dietel B, Wu Y, Beckmann MW, Wrosch JK, Buch-felder M, Eypouoglou Y, Cao Z, Savaskan NE. Identification of two novel chlorotoxin derivatives CA4 and CTX-23 with chemotherapeutic and anti-angiogenic potential. Sci Rep. 2016;6:19799.
22. Crottès D, Rapetti-Mauss R, Alcaraz-Perez F, Tichet M, Gariano G, Martal S, Guizouarn H, Pellissier B, Loubat O, Popa A, Paquet A, Presta M, et al. SIGMAR1 regulates membrane electrical activity in response to extra-cellular matrix stimulation to drive cancer cell invasiveness. Cancer Res. 2016;76:6071–18.

23. Lian GS, Sholl LM, Zakka LR, Liu C, Xu S, Stanek E, Garcia E, Jia Y, MacConaill LE, Murphy GF, Waner M, et al. Novel genetic mutations in a sporadic port-wine stain. JAMA Dermatol. 2014;150:1336–40.

24. Vetrugno R, Ligouris R, Cortelli P, Montagna P. Sympathetic skin response: basic mechanisms and clinical applications. Clin Auton Res. 2009;19:265–70.

25. Maselli RA, Jaspan JB, Soliven BC, Green AJ, Spire JP, Arnason BG. Comparison of sympathetic skin response with quantitative sudomotor axon reflex test in diabetic neuropathy. Muscle Nerve. 1989;12:420–3.

26. Niakan E, Harati Y. Sympathetic skin response in diabetic peripheral neuropathy. Muscle Nerve. 1988;11:261–4.

27. Goizueta-San Martín G, Gutiérrez-Gutiérrez G, Goody-Tundidor H, Mingorance-Goizueta B, Mingorance-Goizueta C, Vega-Piris L, Gutiérrez-Rérez-Rivas E. Sympathetic skin response: reference data for 100 normal subjects. Rev Neurol. 2013;56:231–6.

28. Cappuzzello C, Di Vito L, Melchionna R, Melillo G, Silvestri L, Cesareo E, Buttari B, Segoni L, Profumo E, D’Arcangelo D, Rossi S, Facchiano F, Aguzzi MS, Facchiano F, Ribatti D, Gaeta R, Casadio R, Rossi I, Capogrossi MC, Facchiano A. A novel RGDS-analog inhibits angiogenesis in vitro and in vivo. Biochem Biophys Res Commun. 2004;321:809–14.

29. D’Arcangelo D, Nicodemi EM, Rossi S, Giampietri C, Facchiano F, Faraone D, Aguzzi MS, Toietta G, Facchiano AM, Facchiano F, Magenta M, Hernández-Bule ML, Paíno CL, Trillo MÁ, Úbeda A. Electric stimulation at 448 kHz promotes proliferation of human mesenchymal stem cells. Cell Physiol Biochem. 2014;34:1741–55.

30. Yuan X, Arkonac DE, Chao PG, Vunjak-Novakovic G. Electrical stimulation enhances cell migration and integrative repair in the meniscus. Sci Rep. 2014;4:3674.

31. Chang K-A, Kim JW, Kim JA, Lee SE, Lee S, Kim S, Suh WH, Kim H-S, Kim IS, Song JK, Zhang YL, Lee TH, Cho TH, Song YM, Kim DK, Kim HY, Zhang X, Chung J-Y, Hewitt SM, Miller MC, Veltri RW. A novel quantitative multiplex tissue immunoblotting for biomarkers predicts a prostate cancer aggressive phenotype. Cancer Epidemiol Biomarkers Prev. 2015;24:1864–72.

32. Pinggera A, Siers劲ning J. Cav 1.3 (CACNA1D) L-type Ca(2⁺)-ATPase and cell survival. J Physiol. 2016. doi:10.1113/JP270672.

33. Reinbothe TM, Alkayyali S, Ahlqvist E, Tuomi T, Isomaa B, Lyssenko V, Ristennäs E, The Finnish Type 1 Diabetes Study Group. The human L-type calcium channel Cav1.3 regulates insulin release and polymorphisms in CACNA1D associate with type 2 diabetes. Diabetologia. 2013;56:340–9.

34. Varela MF, Arron Amberg GC, Westenbroek RE, Sinnegger-Brauns MJ, Catuono A. Sympathetic skin response: reference data for 100 normal subjects. Rev Neurol. 2013;56:231–6.

35. Alegre I, Mingorance-Goizueta B, Mingorance-Goizueta C, Vega-Piris L, Gutiérrez-Rérez-Rivas E. Sympathetic skin response: reference data for 100 normal subjects. Rev Neurol. 2013;56:231–6.

36. Shi N, Chen S-Y. From nerve to blood vessel: a new role of Olfm2 in nervous and vascular systems. Annu Rev Cell Dev Biol. 2010;26:639–65.
100. Radvanyi L, Singh-Sandhu D, Gallichan S, Lovatt C, Pedyczak A, Mallo G, Gish K, Kwok K, Hanna W, Zubovits J, Armes J, Venter D, et al. The gene associated with trichorhinophalangeal syndrome in humans is overexpressed in breast cancer. Proc Natl Acad Sci USA. 2005;102:11005–10.

101. Turashvili G, Bouchal J, Baumforth K, Wei W, Dziechciarkova M, Ehrmann J, Klein J, Fridman E, Skarda J, Srovnal J, Hajduch M, Murray P, et al. Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis. BMC Cancer. 2007;7:55.

102. Zhao H, Langerød A, Ji Y, Novels KW, Nesland JM, Tibshirani R, Bukholm IK, Kåresen R, Botstein D, Barresen-Dale A-L, Jeffrey SS. Different gene expression patterns in invasive lobular and ductal carcinomas of the breast. Mol Biol Cell. 2004;15:2523–36.

103. Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, Vasa P, Ladd C, Beheshiti J, Bueno R, Gillette M, Loda M, Weber G, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA. 2001;98:13790–5.

104. Beer DG, Kardia SLR, Huang C-C, Giordano TJ, Levin AM, Misek DE, Lin L, Chen G, Gharib TG, Thomas DG, Lizyness ML, Krick R, et al. Gene expression profiles predict survival of patients with lung adenocarcinoma. Nat Med. 2002;8:816–24.

105. Stearman RS, Dwyer-Nield L, Zerbe L, Blaine SA, Chan Z, Bunn PA, Johnson GL, Hirsch FR, Iafrate AJ, Franklin WA, Baron AE, Rich RL, et al. Analysis of orthologous gene expression between human pulmonary adenocarcinoma and a carcinogen-induced murine model. Am J Pathol. 2005;167:1763–75.

106. Hou J, Aerts J, den Hamer B, van Ijcken W, van Bakker M, Riegman P, van der Leest C, van der Spek P, Fokkens JA, Hoogsteden HC, Grosveld F, Philipsen S. Gene expression-based classification of non-small cell lung carcinomas and survival prediction. PLoS One. 2010;5:e10312.

107. Okayama H, Kohno T, Ishii Y, Shimada Y, Shiraiishi K, Ikakawara R, Fututa K, Tsuta K, Shibata T, Yamamoto S, Watanabe S, Sakamoto H, et al. Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas. Cancer Res. 2012;72:100–11.

108. Selamat SA, Chung BS, Girard L, Zhang W, Zhang Y, Campman M, Siegmund KD, Koss MN, Hagen JA, Lam WL, Lam S, Gazdar AF, et al. Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expression. Genome Res. 2012;22:1197–211.

109. Landi MT, Dracheva T, Rotunno M, Figueroa JD, Liu H, Dasgupta A, Mann FE, Fukuoka J, Hames M, Bergen AW, Murphy SE, Yang P, et al. Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival. PLoS One. 2008;3:e1651.

110. Su L-J, Chang C-W, Wu Y-C, Chen K-C, Lin C-J, Lin C-G, Huang C-YF. Selection of DDX5 as a novel internal control for Q-RT-PCR from microarray data using a block bootstrap re-sampling scheme. BMC Genom. 2007;8:140.